Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 34, Issue 3, Pages 240-245Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2009.02.006
Keywords
Candida spp.; Voriconazole; Time-kill; PK/PD; Modelling; Simulation
Funding
- Pfizer, Inc.
Ask authors/readers for more resources
Using dynamic time-kill experiments with changing voriconazole concentrations, it was demonstrated that Candida albicans ATCC 90029 as well as Candida glabrata and Candida parapsilosis clinical isolates (two each) were significantly inhibited by starting concentrations of 4x and 16x the minimum inhibitory concentration (MIC) but not 1 x MIC. Time-kill data were accurately fitted using a sigmoidal E-max model. Pharmacokinetic (PK) parameters from human data sets were used in the model to simulate kill curves for typical treatment regimens. Simulated curves predicted that voriconazole would exert prolonged fungistatic activity against all five isolates. For three isolates, reductions from starting inocula over 60 h were predicted to exceed 2 log. Combining in vitro time-kill data with existing in vivo PK data might serve as an alternative to animal studies in de. ning optimal antifungal regimens. Published by Elsevier B. V. on behalf of International Society of Chemotherapy
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available